February 2024
Interchangeable Humira Biosimilar Simlandi Joins Market Battle with Unique High-Concentration Formula
Simlandi, interchangeable, Biosimilars, Market
Johnson & Johnson Closes Bay Area R&D Facility, Plans New California Innovation Center
Research and Development, Johnson and Johnson, California, Central
FDA Approves Allecra’s Exblifep, Giving Headstart Over Competition in Complicated Urinary Tract Infections
Urinary tract infection, Complicated
Venatorx Confident in Quick Resolution of Manufacturing Concerns for Cefepime-Taniborbactum Antibiotic Despite FDA Setback
United States Food and Drug Administration, Venatorx, CID, 2024-02-23, cefepime-taniborbactam, Manufacture
Improving Amylyx’s ALS Drug Relyvrio: Taste Masking and Withdrawal
Amylyx, ALS, Relyvrio, Taste Masking, Withdrawal, Patent Life
Novavax Secures $400 Million Settlement with Gavi to Resolve COVID-19 Vaccine Contract Dispute
Gavi, Novavax, Settlement and Resettlement
Limited Role for Immuno-Oncology Despite Record Sales at Bavarian Nordic
Bavarian, Biological Markers
ViiV’s Long-Acting Cabenuva Outperforms Daily Oral Therapy in Phase III Study
cabenuva, Daily, Standard of Care, Adherence (attribute), HIV, Participant, daily
AbbVie CEO Gonzalez to Step Down, Robert Michael named Successor in Seamless Transition
Gonzalez, AbbVie’s, company’s, Transition Mutation
Bayer Implements 95% Dividend Cut to Reduce Debt Amid CEO Bill Anderson’s Turnaround Plan
Bayer, Euro currency, Reduced, 95%